NuCana PLC (NCNA)

NASDAQ
2.110
-0.190(-8.26%)
After Hours
2.110
0.000(0.00%)
- Real-time Data
  • Volume:
    964,801
  • Bid/Ask:
    2.100/2.180
  • Day's Range:
    2.030 - 2.288

NCNA Overview

Prev. Close
2.3
Day's Range
2.03-2.288
Revenue
-
Open
2.26
52 wk Range
2.03-7.83
EPS
-1.18
Volume
964,801
Market Cap
118.82M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
643,790
P/E Ratio
-
Beta
0.74
1-Year Change
-59%
Shares Outstanding
51,662,000
Next Earnings Date
Nov 17, 2021
What is your sentiment on NuCana PLC?
or
Market is currently closed. Voting is open during market hours.

NuCana PLC News

  • NuCana Earnings Miss, Revenue Inline In Q1
    • ByInvesting.com-

    Investing.com - NuCana reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. NuCana announced earnings per...

  • NuCana reports Q1 results
    • BySeeking Alpha-

    NuCana (NCNA): Q1 GAAP EPS of -£0.19.Cash and cash equivalents of £78.6M.Press Release

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsStrong BuyBuyStrong SellStrong SellStrong Sell
SummaryBuyNeutralStrong SellStrong SellStrong Sell

NuCana PLC Company Profile

NuCana PLC Company Profile

Employees
28

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Read More
  • 19💪🍾🍾🍾
    1
    • any news ?
      1
      • I'd like to know. My position is 4,39
        0
    • I've the feeling that this will be a good investment now
      0
      • price is low, but you never know what will happen... can go further down unfortunately !
        0
    • Do you guys suggest to purchase NuCana? It's at 5-98 now.
      1
      • Next one is FBIO
        0
        • Really bro?
          0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.